Your speculation could be very close to reality, Du probably leaned to favor generics even before the trial, during the trial (led by dr Heneckn’s falseful witness) she thought she found a loophole (she thought pto did not review Kura) in pto’s decision and based on the cropped table she drew a wrong conclusion. This is the core of her decision. That is why we should have gone no further than Kura error in appeal, at least we would have heard some discussion during trial and some explanation with the ruling. Not saying we would have won appeal for sure, but at least wouldn’t fail miserably as singer...
Yes, I hope JT can reach out to BPs and let them know what implication of this ruling is to the industry, not by writing letters though, JT should have hanged out (playing some golf for the god sake on our expense) more with other CEOs, but maybe it is too much to ask, the moron can’t even speak...
Hope they can solicit more amicus curie briefs this time. But the sad truth we may only have one that this board funded eventually. Just sad...
News 
Market Data 
Discover 
